Digmbio LOGO

DIGMBIO IN THE NEWS

Digmbio in the News 목록
DigmBio Secures National R&D Grant for Preclinical Development of TAS1R3 Agonist . READ MORE Biospectator Aug 6, 2026
DigmBio Appoints Dr. Byung Gun Lee as Global Management Advisor . READ MORE News 1 July 15, 2026
DigmBio Aims to Initiate Phase 1 Trial of Novel TAS1R3 Agonist for AD Late Next Year This article is available to BioS+ subscribers only.  READ MORE Biospectator July 2, 2026
DigmBio Targets Big Pharma with Next-Gen Brain Metastasis Pipeline . READ MORE MONEYTODAY June 17, 2026
DigmBio and BIK Therapeutics Partner to Co-Develop PARP-1-Targeted Radiopharmaceuticals . READ MORE Hit News June 16, 2026
DigmBio Receives FDA IND Clearance for Phase 2 Trial of DM5167 . READ MORE Hankyung May 19, 2026
DigmBio Selected for Korea’s ‘DIPS 1000+’ . READ MORE Medipana April 13, 2026
19 Korean Biotech Startups Advance to the Global Stage . READ MORE Herald Corporation April 6, 2026
DigmBio and AxcesoBiopharma Partner to Co-develop Next-Generation PARP1 PROTAC-Based Cancer Therapeutics . READ MORE Medigate News Mar 27, 2026
DigmBio to Pursue U.S. Orphan Drug Designation and Accelerated Approval Strategy . READ MORE BIO Insight Feb 27, 2026
Leading the Industry by Developing Next-generation Therapeutics for Cancer and Dementia . READ MORE Hankookilbo Dec 22, 2025
DigmBio Opens Suwon Research Center, Expanding Dual-Hub R&D Across Suwon and Pangyo . READ MORE The Yakup Dec 18, 2025
DigmBio’s Parkinson’s Disease Program Awarded Korea National Drug Development Funding . READ MORE The Yakup Dec 4, 2025
Kim Jeongmin, CEO of DigmBio, presented Digmbio Pipeline at 'BIOLEADERS CLUB' Kim Jeongmin, CEO of DigmBio, said, "The possibility of global technology transfer for our new drug candidate DM5167↑" Kim Jeong-min, CEO of DigmBio, disclosed the development status of the new drug candidate 'DM5167' and future technology transfer strategy at the '25th Bio Leaders Club' hosted by <News 1> on the 24th.https://www.news1.kr/bio/gene . . . READ MORE News 1 June 24, 2025
Kim Jeongmin, CEO of DigmBio, interviewed with the Korea Economic Daily & presented the current pipelines at the Hankyung Bioinsight monthly Interview with CEO Kim Jeong-min June 20, 2025 DM5167, a second-generation PARP inhibitor, is undergoing a phase 1 clinical trial in patients with advanced breast cancer. Partial remission was confirmed at the lowest dose.It is superior to AstraZeneca in efficacy and safety.High brain penetration rate, excellent effect on brain metastasesOptimistic abou . . . READ MORE BIO Insight June 20, 2025

검색